دانلود کتاب روان فارماکولوژی ضروری استال – مبانی عصب شناسی و کاربردهای عملی

For this fifth edition of Stahl’s Essential Psychopharmacology you will notice that every figure in the book has been revised, refreshed, and updated with new colors, shading, and outlining. About half the figures are entirely new. The number of chapters has decreased by one, with merger of mood stabilizers into treatments for mood disorders; the text itself and the total number of figures and tables are all approximately the same in length and number, although all chapters have been edited, most of them extensively, with the details of what has changed listed below. The number of references has now been doubled. Overall, 14 drugs have new uses and indications presented, and 18 brand new drugs are introduced and discussed. Highlights of what has been added or changed since the fourth edition include: • New coverage of interference RNA (iRNA) in basic neuroscience chapters • Restructuring all chapters to reflect neurosciencebased nomenclature, that is, drugs named for their mechanism of action rather than use • Thus, drugs for depression are not “antidepressants” but “monoamine reuptake inhibitors with antidepressant action”; drugs for psychosis are not “antipsychotics” but “serotonin/dopamine antagonists with antipsychotic actions,” etc. • The psychosis chapter has: • new coverage of the direct and indirect striatal dopamine pathways • new coverage of trace amines, receptors, and pharmacology • revision of the classic dopamine theory of psychosis • two new theories of psychosis (serotonin and glutamate) • coverage of dementia-related psychosis and Parkinson psychosis in addition to schizophrenia psychosis • updated coverage of new indications for drugs previously approved, including lurasidone, cariprazine, and brexpiprazole • describes five new drugs for psychosis: lumateperone approved, and xanomeline, pimavanserin, trace amine-associated receptor type 1 (TAAR1) agonists, and roluperidone in development • updated receptor binding data for all drugs • new coverage of tardive dyskinesia and new drug treatments: deutetrabenazine and valbenazine • new coverage of uses of serotonin–dopamine drugs for psychosis that are now used even more frequently for depression • The chapters on mood disorders have: • new coverage of mixed mood states • new coverage of GABAA (γ-aminobutyric acid A) receptor subtypes and neurosteroid binding sites • new coverage of neurotrophic growth factors and neuroplasticity in depression • new coverage of inflammation in depression • mood stabilizers redefined • new/expanded coverage of levomilnacipran, vortioxetine • new coverage of treating cognition in depression • new drugs: neuroactive steroids, ketamine/ esketamine, dextromethorphan combinations, dextromethadone • expanded coverage of treatment resistance and augmentation treatments for monoamine reuptake inhibitors including brexpiprazole, ketamine, esketamine, and trials with cariprazine, pimavanserin • expanded coverage of new hypotheses of neuroplastic downstream changes following NMDA (N-methyl-D-aspartate) antagonist therapy with ketamine, esketamine, and others • expanded coverage of treating bipolar depression with new indications and new drugs lurasidone, cariprazine • The anxiety chapter has: • removal of obsessive–complusive disorder (OCD) to the impulsivity chapter • coverage of posttraumatic stress disorder (PTSD) as a traumatic disorder rather than anxiety disorder • emphasis on anxiety symptoms rather than anxiety disorders • GABA moved to mood chapter • revised discussions on treatments of individual anxiety disorders • renewed emphasis on combining psychotherapy with psychopharmacology for symptoms of anxiety • The pain chapter has: • new criteria for fibromyalgia diagnosis • The sleep chapter has: • much expanded coverage of orexin neuroscience • expanded coverage of histamine neuroscience • much expanded coverage of neurotransmitters across the sleep/wake cycle • presentation of concept of different threshold levels of drugs of different mechanisms in order to induce sleep • expanded coverage of dual orexin receptor antagonists including a new agent lemborexant • discussion of new H3 histamine antagonist, pitolisant, for narcolepsy • discussion of a new wake-promoting norepinephrine–dopamine reuptake inhibitor (NDRI), solriamfetol • expanded circadian rhythm discussion • The attention deficit hyperactivity disorder (ADHD) chapter has: • coverage of multiple new dosage formulations of methylphenidate and amphetamine • discussion of new drugs on the horizon: viloxazine, and others • a presentation of concept of threshold levels necessary for efficacy of stimulants in ADHD • expanded coverage of neurodevelopment in ADHD • The dementia chapter has: • new coverage of acetylcholine and cholinergic receptors • introduction of theories for the circuits of memory versus psychosis versus agitation in dementia • de-emphasis of the amyloid cascade hypothesis